<DOC>
	<DOC>NCT00560690</DOC>
	<brief_summary>Insulin resistance is known to adversely effect viral response to treatment in hepatitis C patients We are aiming to study the effect of an insulin sensitizer, metformin, in viral response of hepatitis C to treatment with pegylated interferon and ribavirin in a double blind randomized controlled trial</brief_summary>
	<brief_title>The Effect of Adding Metformin to the Treatment of Hepatitis C</brief_title>
	<detailed_description>Subjects with hepatitis C will be randomized to receive standard treatment with or without metformin. The results will be compared.</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>chronic hepatitis C Iranian nationality Treatment naive cirrhosis diabetes mellitus HBV/HIV coinfection contraindications of metformin, interferon, ribavirin severe medical conditions (e.g. CHF, CRF, psychosis, ...) not consenting</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>metformin</keyword>
	<keyword>Insulin Resistance</keyword>
</DOC>